Alexandru-Emil Matei

Medizinische Fakultät Professur für Molekulare Mechanismen der Organfibrose Department of Medicine 3 – Rheumatology and Immunology

68GA-FAPI-04 PET/CT STUDY EXTENSION FOR THE ASSESSMENT OF FIBROBLAST ACTIVATION AND RISK EVALUATION IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (2021) Bergmann C, Distler J, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei AE, et al. Conference contribution CIRCULATING MONOCYTES HAVE DISTINCT PHYSICAL PROPERTIES THAT CORRELATE WITH DISEASE ACTIVITY AND SEVERITY AND PREDICT PROGRESSION IN SYSTEMIC SCLEROSIS (2021) Matei AE, Kubankova M, Györfi A, Boxberger E, Soteriou D, Papava M, Muth J, et al. Journal article NCOA3 AMPLIFIES PROFIBROTIC TRANSCRIPTIONAL PROGRAMS IN SYSTEMIC SCLEROSIS (2021) Dees C, Pötter S, Fuchs M, Bergmann C, Matei AE, Györfi AH, Soare A, et al. Conference contribution Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease (2021) Zhang Y, Shen L, Dreißigacker K, Zhu H, Trinh MT, Meng X, Tran Manh C, et al. Journal article X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc) (2021) Bergmann C, Hallenberger L, Chenguiti Fakhouri S, Chenguiti Fakhouri S, Merlevede B, Brandt A, Dees C, et al. Journal article 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study (2021) Bergmann C, Distler J, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei AE, et al. Journal article Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis (2020) Chakraborty D, Zhu H, Juengel A, Summa L, Li YN, Matei AE, Zhou X, et al. Journal article VASCULARIZED THREE-DIMENSIONAL MODELS OF HUMAN SKIN FIBROSIS (2020) Matei AE, Chen CW, Kiesewetter L, Györfi AH, Li YN, Trinh-Minh T, Van Kuppevelt T, et al. Conference contribution FIBROBLAST GROWTH FACTOR RECEPTOR 3 REGULATES THE ACTIVITY OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SYSTEMIC SCLEROSIS (2020) Chakraborty D, Zhu H, Juengel A, Summa L, Li YN, Bergmann C, Matei AE, et al. Conference contribution Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis (2020) Soare A, Györfi AH, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, et al. Journal article